ARTICLE | Company News
Alnylam chemistry news
July 20, 2009 7:00 AM UTC
The European Patent Office upheld Alnylam's European Patent No. EP 1352061 which is part of the Kreutzer-Limmer II patent family. The patent covers the inhibition of about 130 disease targets using double-stranded RNAs (dsRNAs) with or without chemical modifications having a length of up to 49 nucleotides with a 3' nucleotide overhang or 5' blunt end antisense strand. Sirna Therapeutics Inc., now part of Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.), challenged the patent in 2006. ...